Get the Stockscreener App
12.40
1.43%
-0.18
After Hours:
12.40
Dyne Therapeutics Inc stock is traded at $12.40, with a volume of 1.62M.
It is down -1.43% in the last 24 hours and down -10.27% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$12.58
Open:
$12.54
24h Volume:
1.62M
Relative Volume:
0.90
Market Cap:
$1.40B
Revenue:
-
Net Income/Loss:
$-294.51M
P/E Ratio:
-3.4831
EPS:
-3.56
Net Cash Flow:
$-244.42M
1W Performance:
+0.32%
1M Performance:
-10.27%
6M Performance:
-65.94%
1Y Performance:
-54.94%
1-Day Range:
$12.20
$12.62
1-Week Range:
$11.70
$12.81
52-Week Range:
$11.18
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
12.40 | 1.40B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 130.83B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.16B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.89B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.28B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.52B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Stifel maintains Buy on Dyne Therapeutics with $66 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock - Investing.com
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results - Marketscreener.com
Dyne Therapeutics Announces New Long-Term Clinical Data - GlobeNewswire
Dyne : Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months - Nasdaq
Dyne Therapeutics Reports Promising Long-Term Data for DYNE-251 in Duchenne Muscular Dystrophy with Plans for Accelerated Approval Submission - Nasdaq
Game-Changing DMD Clinical Trial: Dyne's DYNE-251 Achieves 8.72% Dystrophin Expression - StockTitan
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World
Dyne wins new Outperform at BMO on prospects for lead drug - MSN
BMO Capital Markets Begins Coverage on Dyne Therapeutics (NASDAQ:DYN) - Defense World
Dyne therapeutics chief commercial officer sells $1,733 in stock By Investing.com - Investing.com Australia
Dyne therapeutics chief commercial officer sells $1,733 in stock - Investing.com
Dyne Therapeutics chief scientific officer sells shares worth $24,501 By Investing.com - Investing.com South Africa
Dyne Therapeutics chief scientific officer sells shares worth $24,501 - Investing.com India
GDX Is Looking To Retest 2020 Highs; Gold To 3K Soon? - The Globe and Mail
Dyne: Accelerated Approval DYNE-101 Might Be Possible With Surrogate Biomarker (DYN) - Seeking Alpha
BMO Capital Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation - MSN
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Benzinga
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating - Yahoo Finance UK
BMO Capital Initiates Dyne Therapeutics Inc at Outperform With $50 Price Target -March 12, 2025 at 07:22 am EDT - Marketscreener.com
Dyne Therapeutics: Innovative Approaches and Promising Clinical Programs Drive Buy Rating - TipRanks
Dyne Therapeutics initiated with an Outperform at BMO Capital - TipRanks
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum - GlobeNewswire
Neuromuscular Disease Breakthroughs: Dyne Therapeutics Reveals Latest Progress at CNS Forum - StockTitan
Dyne Therapeutics (NASDAQ:DYN) Research Coverage Started at Scotiabank - Defense World
Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World
Trend Tracker for (DYN) - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Scotiabank - MarketBeat
Scotiabank Initiates Coverage of Dyne Therapeutics (DYN) with Sector Outperform Recommendation - Nasdaq
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Thinking Of Investing In Dyne Therapeutics Inc (NASDAQ: DYN) Stock? Read This First - Stocks Register
Scotiabank sets Dyne Therapeutics stock target at $50, cites entry point - Investing.com India
Dyne Therapeutics initiated with an Outperform at Scotiabank - TipRanks
Y Intercept Hong Kong Ltd Has $230,000 Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.4% on Analyst Downgrade - Defense World
Dyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Chardan Capital - Defense World
What is HC Wainwright’s Estimate for DYN Q1 Earnings? - Defense World
Piper Sandler Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $48.00 - Defense World
HC Wainwright Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $46.00 - Defense World
Rhumbline Advisers Boosts Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
HC Wainwright Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $46.00 - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells 2,598 Shares of Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Hits New 12-Month LowWhat's Next? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Dyne Therapeutics stock target cut to $46 at H.C. Wainwright By Investing.com - Investing.com Canada
Dyne Therapeutics price target lowered to $48 from $53 at Piper Sandler - TipRanks
RBC Cuts Price Target on Dyne Therapeutics to $41 From $45, Keeps Outperform, Speculative Risk - Marketscreener.com
Buy Rating for Dyne Therapeutics: Promising Accelerated Approval Potential for DYNE-101 and DYNE-251 - TipRanks
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dyne Therapeutics Inc Stock (DYN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scalzo Richard William | SVP, Head of Finance & Admin. |
Mar 11 '25 |
Sale |
11.38 |
1,343 |
15,283 |
122,330 |
| Beskrovnaya Oxana | Chief Scientific Officer |
Mar 11 '25 |
Sale |
11.38 |
2,153 |
24,501 |
195,840 |
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):